問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

孫苑庭

Recruiting

List

7Cases

2024-12-01 - 2028-01-31

Phase III

Active
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine

  • Condition/Disease

    Menstrual Migraine (MM)

  • Test Drug

    NA

Participate Sites
5Sites

Recruiting5Sites

2021-11-01 - 2029-03-18

Phase III

Active
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis

  • Condition/Disease

    Generalized Myasthenia Gravis

  • Test Drug

    注射液 注射液

Participate Sites
5Sites

Recruiting5Sites

2023-07-01 - 2031-10-30

Phase III

Active
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib

  • Condition/Disease

    Relapsing Multiple Sclerosis

  • Test Drug

    Remibrutinib

Participate Sites
4Sites

Recruiting4Sites

2025-01-01 - 2030-12-31

Phase III

Active
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized Myasthenia Gravis, followed by an open-label extension phase

  • Condition/Disease

    Generalized Myasthenia Gravis

  • Test Drug

    Remibrutinib

Participate Sites
5Sites

Recruiting5Sites

2020-07-15 - 2026-07-31

Phase IV

Active
A 12-month, Prospective, Multi-center Post-authorization Commitment (PAC) Study Monitoring Safety in Adult Patients With Relapsing-remitting Multiple Sclerosis Newly Initiated on Gilenya (Fingolimod) in Taiwan (SPRING)

  • Condition/Disease

    Multiple Sclerosis

  • Test Drug

    Gilenya hard Capsules 0.5mg

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2020-01-01 - 2025-12-31

Phase III

Completed
A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Condition/Disease

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Test Drug

    ENSPRYNG 120mg for SC Injection

Participate Sites
4Sites

Recruiting4Sites

2021-11-01 - 2027-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB